drugset / Trial / NCT02968160

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

NCT02968160

Phase 4 Terminated 55 enrolled Yuhan Corporation Linical Korea · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Randomized, open-label, 2 groups, parallel design.

Timeline

Start
2016-10
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 20 mg Oral
Subject Telmisartan Other / unclassified 40 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications